This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hedge Funds Hate These 5 Stocks -- but Should You?


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

2013 is panning out to be a good year for AmerisourceBergen (ABC - Get Report). Shares of the pharmaceutical distributor have climbed almost 9% year-to-date, topping even the impressive performance of the S&P over that same period. But hedge funds have missed out on those gains. Funds sold off 7.43 million shares of ABC last quarter, cutting their stake in the firm by 84%. So, was it worth it? In my view, yes.

AmerisourceBergen is one of the biggest pharmaceutical distributors in the U.S., a business that involves acting as a middleman between pharmaceutical manufacturers and healthcare providers. It's a business that provides slim margins -- after all, if profitability grew too attractive pharmaceutical and healthcare firms could just fire the middleman and replicate ABC's offerings internally.

In other words, AmerisourceBergen is attractive because its business isn't.

Even though health care reforms should provide ABC with some tailwinds in the next couple of years, extremely tight competition and an industry ruled by oligarchy make finding an edge difficult. AmerisourceBergen may be the most attractive distributor in the industry, but I'd rather avoid pharma distributors in toto.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ABC $84.55 -1.23%
AAPL $93.70 -0.60%
GE $27.45 -3.00%
MSFT $49.69 -0.04%
WFC $45.16 -2.19%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs